证券代码：000534 证券简称：万泽股份 万泽实业股份有限公司 投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |----------------|------------------------|---------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 博时基金管理有限公司 | 田野 | | 人员姓名 | 方正证券股份有限公司 | 杨诚笑 | | | 方正证券股份有限公司 | 孙亮 | | | 方正证券股份有限公司 | 陈文坚 | | | 方正证券股份有限公司 | 蔡靖 | | | 英大证券有限责任公司 | 孙超 | | | 天宏基金管理有限公司 | 田俊维 | | | 东吴基金管理有限公司 | 高人元 | | | 广发证券 赵炳楠 | | | | 广发证券 胡正洋 | | | | ...

证券代码：000534 证券简称：万泽股份 万泽实业股份有限公司 投资者关系活动记录表 编号：2016-01 | --- | --- | --- | |----------------|------------------------------|---------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 国信证券股份有限公司 | 詹俊鹏 | | 人员姓名 | 金元证券股份有限公司 | 汪敬波 | | | 海通证券股份有限公司 | 田源 | | | 宝盈基金 陈金伟 | | | | 摩根士丹利华鑫基金 | 朱睿 | | | 摩根士丹利华鑫基金 齐兴芳 | | | | 中银国际证券有限责任公司 | 张铖 | | | 东方证券 姚婕 | | | | 平安资产管理有限责任公司 | 马克明 | | | 天弘基金管理有限公司 | 李佳 ...

证券代码：000534 证券简称：万泽股份 万泽实业股份有限公司 投资者关系活动记录表 编号：2019-01 | --- | --- | --- | |----------------|-------------------------|---------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 安信证券 冯福章、张傲 | | | 人员姓名 | 国泰基金 高亮 | | | | 泰信基金 刘杰 | | | | 中庚基金 季国峰 | | | | 高毅资产 庞韬 | | | | 华泰柏瑞基金 | 孙婕衎 | | | 交银基金 郭若 | | | | 鼎萨资产 陈峰 | | | | 上海军民融合基金 | 赵大地 | | | 翌沛投资 陈钢 | | | 时间 | 2019 年 9 月 24 | 日下午 | 1 | --- | --- | ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥206,696,246.69, representing a year-over-year increase of 9.21%[5]. - Net profit attributable to shareholders for the same period was ¥21,041,930.49, a slight increase of 0.06% compared to the previous year[5]. - The net profit excluding non-recurring gains and losses reached ¥15,996,767.42, up 12.53% year-over-year[5]. - Total operating revenue for the third quarter reached ¥581,328,333.12, an increase of 23.9% compared to ¥469,317,731.14 in the same period last year[63]. - Net profit for the period was ¥98,557,830.45, representing a 25% increase from ¥78,947,152.15 in the previous year[66]. - Total comprehensive income amounted to ¥98,557,830.45, an increase from ¥78,947,152.15 in the previous period[70]. - Net income attributable to the parent company was ¥95,584,195.05, up from ¥85,149,613.97 year-over-year[70]. - Basic earnings per share increased to ¥0.1922 from ¥0.1731, while diluted earnings per share rose to ¥0.1894 from ¥0.1719[70]. Cash Flow and Liquidity - Cash flow from operating activities showed a significant decline, with a net amount of ¥21,593,345.37, down 71.21% compared to the same period last year[5]. - Cash inflows from operating activities totaled ¥592,602,213.29, compared to ¥541,529,840.89 in the prior period[73]. - Net cash flow from operating activities decreased to ¥21,593,345.37 from ¥74,991,746.44 year-over-year[73]. - Cash outflows from investing activities were ¥294,869,102.15, down from ¥372,849,337.86 in the previous period[77]. - Net cash flow from investing activities was -¥293,521,368.04, worsening from -¥144,599,504.44 year-over-year[77]. - Cash inflows from financing activities increased to ¥299,660,498.84 from ¥134,670,541.37[77]. - Net cash flow from financing activities improved to ¥114,130,554.11 from -¥155,768,603.56 year-over-year[77]. - The ending balance of cash and cash equivalents was ¥159,226,199.00, slightly down from ¥159,749,222.35 in the previous period[79]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,307,440,965.43, an increase of 8.97% from the end of the previous year[5]. - The company's total assets increased to ¥2,307,440,965.43, compared to ¥2,117,454,697.21, marking a growth of 9%[58]. - The total liabilities increased to ¥1,084,532,061.66, up from ¥1,017,964,343.14, reflecting a growth of 6.5%[58]. - The total current assets decreased to ¥611,263,227.36 as of September 30, 2022, from ¥663,389,003.51 on January 1, 2022, representing a decline of approximately 7.9%[50]. Equity and Shareholder Information - The total equity attributable to shareholders increased by 10.19% to ¥1,180,289,800.48 compared to the end of the previous year[5]. - The equity attributable to shareholders of the parent company increased to ¥1,180,289,800.48 from ¥1,071,171,820.88, reflecting a growth of 10.2%[58]. - The company approved adjustments to the exercise price of stock options under the 2020 equity incentive plan from ¥13.64 per share to ¥13.59 per share[45]. - The company granted 4.995 million restricted shares under the 2021 equity incentive plan at a price of ¥7.70 per share[46]. - The company plans to adjust the repurchase price of restricted shares under the 2021 equity incentive plan from ¥7.70 per share to ¥7.65 per share[46]. - A total of 927,900 restricted shares were released for trading on April 19, 2022, following the completion of the first unlock period[40]. - The company has not disclosed any known relationships among the top shareholders or whether they are acting in concert as defined by the regulations[36]. Research and Development - The company's R&D expenditure increased by 173.87% compared to the beginning of the period, reflecting a stronger focus on innovation[17]. - Research and development expenses decreased to ¥45,627,246.42 from ¥49,068,106.23, a reduction of 7.4%[63]. Accounts Receivable and Inventory - The number of accounts receivable increased by 91.84%, primarily due to a significant rise in sales volume of high-temperature alloy products[13]. - Accounts receivable increased to ¥247,461,479.88 as of September 30, 2022, compared to ¥128,991,111.94 on January 1, 2022, reflecting a growth of approximately 92.1%[50]. - Inventory as of September 30, 2022, was ¥128,683,745.13, up from ¥102,004,036.62 on January 1, 2022, indicating an increase of about 26.1%[50]. Operating Costs - The company reported a 39.70% increase in operating costs year-over-year, attributed to higher sales volumes[25]. - Total operating costs amounted to ¥470,320,849.76, up from ¥437,482,348.27, reflecting a year-over-year increase of 7.6%[63]. Other Information - The company experienced a 100% decrease in non-current assets due within one year, mainly due to the repayment of financing lease loans[12]. - The company has not reported any significant new product developments or market expansions in the recent quarter[39]. - Long-term equity investments rose to ¥9,527,587.54 from ¥9,168,917.89, indicating a year-over-year increase of 3.9%[58]. - The company reported a significant increase in contract liabilities, which rose to ¥4,162,548.20 from ¥2,395,039.87, a growth of 74%[56].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥374,632,086.43, representing a 33.78% increase compared to ¥280,044,176.91 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was ¥74,542,264.56, up 16.25% from ¥64,119,929.34 year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥62,012,240.94, a significant increase of 178.46% compared to ¥22,269,365.88 in the previous year[26]. - Basic earnings per share were ¥0.1496, up 15.25% from ¥0.1298 in the same period last year[26]. - The diluted earnings per share were ¥0.1474, an increase of 14.35% compared to ¥0.1289 in the previous year[26]. - The weighted average return on net assets was 6.71%, an increase of 0.46 percentage points from 6.25% in the previous year[26]. Cash Flow and Assets - The net cash flow from operating activities was -¥22,416,225.97, a decrease of 173.08% from ¥30,674,776.38 in the same period last year[26]. - The total assets at the end of the reporting period were ¥2,369,267,045.73, an increase of 11.89% from ¥2,117,454,697.21 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company were ¥1,143,727,378.04, reflecting a 6.77% increase from ¥1,071,171,820.88 at the end of the previous year[26]. - Cash and cash equivalents decreased to ¥310,951,206.87, accounting for 13.12% of total assets, down 2.03 percentage points from the previous year[65]. - Accounts receivable increased to ¥207,972,861.13, representing 8.78% of total assets, up 2.69 percentage points due to revenue growth[65]. - Inventory rose to ¥128,777,525.77, making up 5.44% of total assets, an increase of 0.62 percentage points[65]. - Short-term borrowings increased to ¥205,474,510.55, which is 8.67% of total assets, up 1.51 percentage points due to increased funding needs from business growth[65]. - Long-term borrowings rose to ¥349,968,890.39, accounting for 14.77% of total assets, an increase of 2.00 percentage points[65]. Business Operations and Growth - The main business of the company includes the research, production, and sales of micro-ecological live bacteria products and high-temperature alloys[37]. - The company achieved a 50% growth in the clinical market for its product "Dingjunsheng" during the reporting period[39]. - The company has launched a new product, "Wanze Shuangqi Three-Component Probiotic Powder," in July 2022, expanding its product line in the health food sector[41]. - The company has completed the construction of its Zhuhai base and Shenzhen Wanze Microbiology Research Institute, with plans for formal operation by the end of 2022[41]. - The company has a production capacity of 100 pieces/year for powder discs, 100 tons/year for powder, and 60 tons/year for master alloys at its Shen-Shan facility[44]. - The company has initiated over 20 projects in high-temperature alloy blade technology, with 15 projects completed and over 2,000 finished products delivered during the reporting period[43]. - The company has established a comprehensive marketing system covering prescription drugs, OTC products, and health foods, collaborating with over 3,000 hospitals and 100,000 pharmacies nationwide[47]. - The company is focused on expanding its market presence and enhancing its research capabilities in the probiotic field through strategic partnerships[39]. Research and Development - The company's research and development expenses amounted to ¥58,234,709.45, which is a 21.70% increase from the previous year[56]. - The company has established a complete R&D and testing system for high-temperature alloys, achieving several key technological breakthroughs and obtaining multiple patents[49]. - The company has formed stable long-term partnerships with several domestic research institutions and enterprises in the high-temperature alloy field[49]. Financial Management and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[6]. - The company held three temporary shareholder meetings in 2022, with investor participation rates of 46.63%, 46.60%, and 46.36% respectively[86]. - The total number of shares increased from 495,713,096 to 500,623,096 due to stock incentives[145]. - The total number of common shareholders at the end of the reporting period was 19,610, with the largest shareholder, Wanze Group Co., Ltd., holding 39.47% of shares, equating to 197,608,136 shares[159]. - The company’s stock incentive plans are aimed at aligning the interests of management and shareholders[153]. Environmental and Regulatory Compliance - The company has not faced any administrative penalties related to environmental issues during the reporting period[101]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[102]. - The company has established a comprehensive internal control system to protect the interests of shareholders, especially minority shareholders, by implementing a management mechanism that balances the powers of the shareholders' meeting, board of directors, and supervisory board[103]. Miscellaneous - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[165]. - There were no significant litigation or arbitration matters during the reporting period[114]. - The half-year financial report has not been audited[110].

Financial Performance - The company's operating revenue for Q1 2022 was ¥136,369,239.24, a decrease of 1.75% compared to ¥138,801,271.38 in the same period last year[5] - Net profit attributable to shareholders was ¥32,656,024.39, down 25.88% from ¥44,060,661.71 year-on-year[5] - Basic earnings per share decreased by 27.01% to ¥0.0654 from ¥0.0896 in the same period last year[5] - Total operating revenue for the current period is $136.37 million, a decrease of 1.03% from $138.80 million in the previous period[35] - Net profit for the current period is $31.53 million, a decrease of 23.83% compared to $41.44 million in the previous period[38] - Basic earnings per share for the current period is $0.0654, down from $0.0896 in the previous period[38] Cash Flow - The net cash flow from operating activities was -¥86,498,490.82, a significant decline of 287.63% compared to ¥46,101,428.17 in the previous year[5] - Cash flow from operating activities shows a net outflow of $86.50 million, compared to a net inflow of $46.10 million in the previous period[42] - Net cash flow from investment activities was -$123.67 million, compared to -$85.50 million in the previous period, indicating a decline in investment performance[45] - Total cash inflow from financing activities reached $185.77 million, significantly higher than $36.66 million in the prior period, reflecting increased financing efforts[45] - Net cash flow from financing activities was $172.93 million, a substantial improvement from -$80.74 million previously, showcasing effective capital management[45] - Cash flow from operating activities was not detailed, but the overall cash and cash equivalents decreased by $37.32 million compared to a decrease of $120.14 million previously, indicating improved cash management[45] Assets and Liabilities - Total assets increased by 8.36% to ¥2,294,402,329.36 from ¥2,117,454,697.21 at the end of the previous year[5] - Total liabilities increased to ¥1,158,595,181.14 from ¥1,017,964,343.14, an increase of approximately 13.8%[31] - The company's equity attributable to shareholders increased to ¥1,108,616,070.36 from ¥1,071,171,820.88, a growth of approximately 3.5%[31] - Non-current assets totaled ¥1,601,963,396.27, up from ¥1,454,065,693.70, indicating an increase of about 10.1%[28] Expenses - Research and development expenses decreased by 72.83% compared to the same period last year, primarily due to a reduction in R&D projects[17] - Management expenses rose by 32.55% compared to the previous year, primarily due to the implementation of stock incentives[16] - Sales expenses decreased to $45.08 million, a reduction of 5.69% from $47.49 million in the previous period[35] - Credit impairment losses decreased significantly to $951.66 thousand, down 94.69% from $17.96 million in the previous period[35] Financing and Borrowings - The company reported a 41.93% increase in short-term borrowings, attributed to new loans taken out[13] - Short-term borrowings rose to ¥215,225,525.02 from ¥151,643,729.27, reflecting an increase of about 42.0%[31] - The company received $147.29 million in cash from borrowings, a significant increase from $14.88 million in the previous period, highlighting enhanced borrowing capacity[45] - Cash outflow for debt repayment was $6.91 million, a decrease from $109.78 million in the previous period, indicating reduced debt servicing pressure[45] Other Income and Subsidies - The company received government subsidies amounting to ¥14,680,573.29 during the reporting period[8] - Other income increased to $14.68 million, up 66.67% from $8.79 million in the previous period[35] Stock and Equity - The company completed the registration of 4,995,000 restricted stocks under the 2021 equity incentive plan at a grant price of ¥7.70 per share[24] - The capital reserve increased by 132.40%, mainly due to the inclusion of stock incentive expenses[15] Inventory and Receivables - Accounts receivable decreased to ¥111,991,657.81 from ¥128,991,111.94, representing a decrease of approximately 13.2%[25] - Inventory increased to ¥128,987,508.91 from ¥102,004,036.62, showing an increase of about 26.4%[25] Audit and Reliability - The first quarter report was not audited, which may affect the reliability of the financial data presented[46]

Financial Performance - The company's operating revenue for 2021 was ¥656,255,549.80, an increase of 18.77% compared to ¥552,561,979.41 in 2020[28]. - The net profit attributable to shareholders for 2021 was ¥95,292,383.72, representing a 24.20% increase from ¥76,725,841.36 in 2020[28]. - The net profit after deducting non-recurring gains and losses was ¥46,484,032.82, a significant increase of 254.69% from ¥13,105,574.38 in 2020[28]. - The company's cash flow from operating activities for 2021 was ¥136,667,738.73, a decrease of 4.04% compared to ¥142,422,522.82 in 2020[28]. - The basic earnings per share for 2021 was ¥0.1926, up 23.46% from ¥0.156 in 2020[28]. - The weighted average return on equity increased to 9.20% in 2021, up by 1.32 percentage points from 7.88% in 2020[28]. - The total assets at the end of 2021 were ¥2,117,454,697.21, a slight decrease of 0.39% from ¥2,125,769,141.68 at the end of 2020[28]. - The net cash flow from operating activities was 136,667,738.73 CNY, a decrease of 4.04% compared to the previous year[88]. - The cash and cash equivalents decreased by 68,734,324.44 CNY, marking a 133.66% decline compared to the previous year[88]. - The company reported a total asset value of ¥856,247,645.83 for Inner Mongolia Shuangqi Pharmaceutical Co., Ltd., indicating a strong asset base in the pharmaceutical sector[109]. Business Strategy and Expansion - The company shifted its main business focus from power generation to the R&D, manufacturing, sales, and maintenance of high-temperature alloys and related technical services[25]. - The company plans to expand its operations into the pharmaceutical industry, which was approved in a shareholder meeting on September 30, 2019[25]. - The company is constructing a new production base in Zhuhai, expected to be operational by 2024, enhancing its production capacity for micro-ecological preparations[56]. - The company has established a comprehensive marketing system covering prescription drugs, OTC products, and health foods, collaborating with over 3,000 hospitals and 100,000 pharmacies nationwide[49]. - The company is focusing on optimizing its organizational structure to enhance management efficiency and talent development[116]. - The company is committed to increasing R&D investment in high-temperature alloy materials, targeting applications in aerospace and power generation sectors[117]. - The company is actively expanding its product line and developing new profit points in the micro-ecological live bacteria product business[122]. Research and Development - The company has developed a complete R&D and testing system for superalloy materials, achieving multiple key technological breakthroughs and obtaining several patents related to superalloy business[53]. - In 2021, the company applied for 13 invention patents, with 8 granted, and owns 42 registered trademarks[56]. - The company completed 49 out of 53 planned R&D projects in high-temperature alloy blades, delivering 7,474 finished turbine blades in 2021[57]. - The company plans to develop approximately 10 new probiotic strains annually as part of its ongoing research projects[79]. - The company has established a microbiology research institute in the Greater Bay Area to enhance research and incubation capabilities in the micro-ecological field[112]. Governance and Management - The company has a robust governance structure, ensuring compliance with relevant laws and regulations[128]. - The company is focused on maintaining stable management and governance structures, ensuring continuity in leadership roles[142]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.4852 million yuan, with 11 out of 13 individuals receiving compensation[153]. - The company has established a performance-based bonus system for senior management, linked to their work performance and the company's operational results[153]. - The independent directors have actively participated in board meetings and provided objective opinions on major decisions, ensuring effective governance[172]. Shareholder Engagement and Dividends - The company reported a cash dividend of 0.5 yuan per 10 shares (including tax) to all shareholders, with no bonus shares issued[6]. - The company approved a three-year dividend return plan for 2021-2023 during the annual shareholder meeting[133]. - The company plans to distribute a cash dividend of CNY 0.50 per 10 shares (tax included), totaling CNY 25,035,404.80, which represents 100% of the profit distribution amount[186]. - The company has established a three-year dividend plan (2021-2023) to protect the rights of minority investors and ensure a sustainable dividend mechanism[184]. - The company has consistently maintained a cash dividend payout ratio exceeding 30% from 2018 to 2020[166]. Risks and Challenges - The company faces risks related to profitability during its strategic transition, relying on stable cash flow from its microbiological products to support high-temperature alloy business growth[118]. - The company is addressing the risk of declining drug prices due to national procurement policies that compress sales margins for pharmaceutical companies[119]. - The company has faced continuous losses since the establishment of its wholly-owned subsidiary in February 2020, raising concerns about the necessity of further capital increases[168]. - The company has opposed several proposals related to stock incentive plans, citing concerns over their impact on minority shareholders[168]. Employee and Stock Incentive Plans - The total number of employees at the end of the reporting period is 1,038, with 27 in the parent company and 1,011 in major subsidiaries[179]. - The average salary for executives is CNY 316,800 per person, while the average salary for all employees is CNY 152,500 per person[182]. - The company granted a total of 8 million stock options and 4 million restricted stocks under the 2020 equity incentive plan, with an exercise price of ¥13.70 per option and a grant price of ¥6.85 per share[190]. - The company’s equity incentive plans are designed to align the interests of employees with those of shareholders, enhancing overall company performance[192]. - The company continues to focus on expanding its equity incentive programs to include a broader range of employees, thereby increasing engagement and productivity[193].

Revenue and Profit - Revenue for Q3 2021 reached ¥189,273,554.23, an increase of 34.09% year-over-year[5] - Net profit attributable to shareholders was ¥21,029,684.63, up 2.35% compared to the same period last year[5] - Net profit excluding non-recurring gains and losses decreased by 18.47% to ¥14,216,066.86[5] - Total operating revenue for the current period reached ¥469,317,731.14, an increase of 26.1% compared to ¥372,138,256.56 in the previous period[30] - Net profit for the current period was ¥78,947,152.15, representing a 27.7% increase from ¥61,802,979.13 in the previous period[32] - Earnings attributable to the parent company's shareholders were ¥85,149,613.97, compared to ¥69,599,466.25 in the previous period, reflecting a growth of 22.4%[32] - Basic earnings per share increased to ¥0.1731 from ¥0.1415, marking a rise of 22.5%[32] Cash Flow - Operating cash flow increased significantly by 414.00%, totaling ¥74,991,746.44 year-to-date[5] - The net cash flow from operating activities increased significantly, driven by higher sales compared to the previous year[13] - Cash flow from operating activities netted at ¥74,991,746.44, a significant improvement from a negative ¥37,760,075.75 in the previous period[37] - Cash inflow from investment activities totaled ¥228,249,833.42, down from ¥353,220,596.61 in the prior period, resulting in a net cash outflow of ¥144,599,504.44[40] - Cash flow from financing activities resulted in a net outflow of ¥155,768,603.56, compared to a smaller outflow of ¥75,681,924.93 last year[40] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,031,268,799.17, a decrease of 4.45% from the previous year[5] - Total liabilities decreased to ¥977,886,408.64 from ¥1,134,034,516.54, a reduction of 13.8%[30] - Current liabilities decreased to ¥506,071,610.61 from ¥666,903,907.91, a reduction of approximately 24.1%[23] - Total assets decreased to ¥2,031,268,799.17 from ¥2,125,769,141.68, reflecting a decline of about 4.4%[23] - Total equity attributable to the parent company increased to ¥1,033,818,279.17 from ¥999,767,746.84, an increase of 3.4%[30] Expenses - The company reported a 60.28% increase in operating costs compared to the same period last year[13] - Management expenses rose by 38.45% year-over-year, primarily due to the implementation of equity incentives[13] - Research and development expenses for the current period were ¥49,068,106.23, up from ¥45,436,426.48, indicating a growth of 5.7%[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 16,873, with the largest shareholder, Wanze Group Co., Ltd., holding 39.92% of shares, equating to 197,608,136 shares[14] Other Financial Information - The company experienced a 255.13% decrease in credit impairment losses, reflecting the recovery of bad debt provisions[13] - Other income increased by 36.35% year-over-year, attributed to increased government subsidies received by subsidiaries[13] - The company reported a financial asset impairment loss of ¥14,727,444.17, compared to a gain of ¥9,493,591.19 in the previous period[30] - The company has not disclosed any new product or technology developments in the current report[18] - There are no significant mergers or acquisitions reported during this period[18] - The report for the third quarter was not audited, indicating a need for caution in interpreting the financial data[51]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥280,044,176.91, representing a 21.24% increase compared to ¥230,984,776.25 in the same period last year[27]. - The net profit attributable to shareholders of the listed company was ¥64,119,929.34, a 30.72% increase from ¥49,052,915.31 year-on-year[27]. - The net profit after deducting non-recurring gains and losses surged by 597.80%, reaching ¥22,269,365.88 compared to ¥3,191,387.18 in the previous year[27]. - The net cash flow from operating activities improved significantly to ¥30,674,776.38, a 521.13% increase from a negative cash flow of ¥7,283,908.76 in the same period last year[27]. - Basic earnings per share increased by 30.19% to ¥0.1298, while diluted earnings per share rose by 29.29% to ¥0.1289[27]. - The weighted average return on equity increased by 1.21 percentage points to 6.25% compared to 5.04% in the previous year[27]. - The company's gross profit margin in the pharmaceutical manufacturing sector was 87.66%, with a year-on-year decrease of 1.12 percentage points[51]. - The revenue from the pharmaceutical manufacturing sector accounted for 90.91% of total operating revenue, amounting to ¥254,593,507.73, up from ¥218,388,802.52, reflecting a growth of 16.58%[51]. - The company reported a significant increase in revenue from the non-ferrous metal smelting and processing industry, which grew by 73.46% to ¥21,556,638.06, compared to ¥12,427,722.42 in the previous year[51]. - The company reported a total investment income of CNY 36,819,438.88 from trading financial assets and derivatives[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,016,906,745.91, a decrease of 5.12% from ¥2,125,769,141.68 at the end of the previous year[27]. - The cash and cash equivalents decreased by 8.59 percentage points to 9.98% of total assets, totaling ¥201,355,587.86, down from ¥394,745,353.21[56]. - The company's long-term equity investments increased slightly by 0.05 percentage points to 0.45% of total assets, amounting to ¥9,026,661.64[56]. - The total amount of non-operating funds occupied by the controlling shareholder and related parties at the beginning of the period was CNY 137.31 million, with an increase of CNY 2.04 million during the reporting period[100]. - The total amount repaid during the reporting period was CNY 139.35 million, resulting in a year-end balance of CNY 0[100]. - The company's total liabilities remain at 0.00 CNY, indicating no financial liabilities reported[59]. - Total liabilities decreased from CNY 1,134,034,516.54 to CNY 988,554,126.84, a reduction of about 12.8%[179]. - Current liabilities decreased from CNY 666,903,907.91 to CNY 514,540,619.95, a decline of approximately 22.9%[179]. - Long-term borrowings slightly decreased from CNY 305,570,242.42 to CNY 300,403,611.11, a decrease of about 1.4%[179]. Strategic Initiatives - The company plans to launch a new probiotic dietary supplement "Today Probiotics" by the end of the year, expanding its product line[39]. - The Zhuhai production base construction has commenced and is expected to be operational by 2024[39]. - The company is undergoing a strategic transformation, focusing on the industrialization of high-temperature alloy business while relying on stable income from microbial agents[75]. - The company plans to invest in a micro-ecological research center to enhance its R&D capabilities for new products in response to pricing pressures in the pharmaceutical sector[76]. - The company has identified strategic opportunities for mergers and acquisitions to enhance its competitive position in the market[197]. Research and Development - The company has established a complete R&D system for high-temperature alloys, with a core team of experts from the aerospace and gas turbine sectors[48]. - The company has developed multiple proprietary high-temperature alloy materials and holds several patents in this field[48]. - Research and development expenses rose by 13.06% to ¥32,414,524.53, compared to ¥28,670,233.09 in the previous year[49]. - The company has invested CNY 20,063,645.37 in development expenditures, up from CNY 4,627,567.03, indicating a significant increase in R&D efforts[176]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[7]. - The employee stock ownership plan raised a total of 25 million RMB, with 2,736,997 shares purchased, accounting for 0.56% of the total share capital at an average price of 9.13 RMB per share[5]. - The total number of shares increased from 491,785,096 to 494,963,096, with a new issuance of 3,178,000 shares[141]. - The total number of unrestricted shares remained at 491,507,596, accounting for 99.30% of total shares after the change[141]. - Total number of common shareholders at the end of the reporting period was 16,923, with the largest shareholder, Wanze Group, holding 42.01% (207,934,027 shares)[151]. Compliance and Governance - The company has established a robust internal control system to protect the interests of shareholders, especially minority shareholders[94]. - The company has not engaged in any significant related party transactions during the reporting period[109]. - There were no major litigation or arbitration matters during the reporting period[106]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[105]. - The half-year financial report has not been audited[104]. - The company has not provided any guarantees that violate regulations during the reporting period[103].

Financial Performance - The company's operating revenue for Q1 2021 was ¥138,801,271.38, a decrease of 18.00% compared to the same period last year[10]. - Net profit attributable to shareholders was ¥44,060,661.71, down 2.36% year-on-year[10]. - The net profit excluding non-recurring gains and losses increased by 7.25% to ¥36,880,385.12[10]. - Net profit for Q1 2021 was ¥41,444,609.13, a decrease of 7.0% from ¥44,936,861.05 in Q4 2020[90]. - The company’s net profit for the reporting period was CNY 552,043,312.55, an increase from CNY 507,982,650.84[73]. - The company achieved an investment income of ¥442,165.02 compared to a loss of ¥40,522.45 in the previous quarter[90]. - Investment income increased by 1191.16% compared to the same period last year, primarily due to profits from associated companies[31]. - Non-operating income increased by 1039.97% compared to the same period last year, primarily due to penalties received from suppliers for delayed deliveries, with no related income in the previous period[31]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 56.83% to ¥46,101,428.17[10]. - Cash and cash equivalents decreased by 30.46% compared to the beginning of the period, mainly due to repayment of due loans[22]. - Cash flow from operating activities generated a net amount of ¥46,101,428.17, down from ¥106,796,911.40 in the previous period[104]. - Cash inflow from operating activities totaled ¥173,730,095.39, compared to ¥217,274,815.69 in the previous period[104]. - Cash outflow from operating activities was ¥127,628,667.22, compared to ¥110,477,904.29 in the previous period[104]. - The ending balance of cash and cash equivalents was 31,913,717.65 yuan, down from 1,733,487.32 yuan in the previous period[113]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,094,752,856.76, a decrease of 1.46% from the end of the previous year[10]. - The company's total liabilities were CNY 1,036,704,723.49, down from CNY 1,134,034,516.54[71]. - Total liabilities decreased to ¥620,852,390.53 from ¥641,057,647.56 at the end of 2020, a reduction of 3.5%[84]. - Total equity attributable to shareholders of the parent company increased to CNY 1,068,697,307.55 from CNY 999,767,746.84[73]. - The total assets of the company were CNY 2,125,769,141.68, reflecting a decrease of CNY 19,572,513.62 compared to the previous period[121]. - Current liabilities totaled CNY 666,903,907.91, down from CNY 672,799,767.24, a reduction of CNY 5,895,859.33[121]. - Non-current liabilities decreased to CNY 467,130,608.63, down by CNY 13,676,654.29 from the previous period[121]. Research and Development - The development expenditure increased by 174.09%, reflecting ongoing capitalization of R&D projects[22]. - Research and development expenses increased by 51.14% compared to the same period last year, mainly due to new R&D projects and increased investment in R&D by various subsidiaries[29]. - Research and development expenses were reported at ¥9,453,640.42, an increase from ¥4,353,708.18 in the previous period[98]. Other Financial Metrics - Cash and cash equivalents as of March 31, 2021, were CNY 274,511,352.53, compared to CNY 394,745,353.21 at the end of the previous period[65]. - The company reported a credit impairment loss of ¥17,022,869.76, compared to a loss of ¥485,594.67 in the previous period[98]. - Other income decreased by 36.94% compared to the same period last year, mainly due to a reduction in government subsidies received by subsidiaries[30]. - Other current liabilities increased by 87.70% at the end of the period compared to the beginning, mainly due to the increase in advance payments received by the subsidiary Shanghai Wanze Precision Casting Co., Ltd., leading to a corresponding increase in input VAT to be transferred[26]. Miscellaneous - The company has not engaged in any investor relations activities during the reporting period[60]. - The first quarter report for 2021 was not audited[129]. - The company implemented new leasing standards since January 1, 2021, affecting the measurement of lease liabilities and right-of-use assets[121].